Publish in this journal
Journal Information
Share
Share
Download PDF
More article options
ePub
Visits
...
Brief Report
Available online 23 December 2021
Anti-TNFα drug levels in patients with rheumatoid arthritis and spondyloarthritis
Niveles de fármacos anti-TNFα en pacientes con artritis reumatoide y espondiloartritis
Visits
...
Erardo Meriño-Ibarra
Corresponding author
eemerinnoi@salud.aragon.es

Corresponding author.
, Francisco Javier Manero Ruíz
Servicio de Reumatología, Hospital Universitario Miguel Servet, Zaragoza, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (2)
Table 1. Summary of variables assessed, by rheumatic disease.
Table 2. Anti-TNF drug levels in standard-dose patients. A: Overall results. B: Anti-TNF drug levels according to rheumatic disease and according to remission/low disease activity vs. no remission/no low disease activity. C: Drug levels according to treatment with DMARDs and C1 according to rheumatic disease.
Show moreShow less
Abstract
Background and objectives

Knowledge of the levels of anti-TNFa drugs can modify treatment in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA).

Objectives

To compare the levels of anti-TNFa in patients with RA vs SpA, in different clinical situations.

Materials and methods

A retrospective, observational study was conducted. Levels of anti-TNFa and the presence of anti-drug antibodies were measured in consecutively selected patients, using the ELISA technique.

Results

Fifty-three, 73 and 78 patients treated with infliximab, adalimumab and etanercept were studied, respectively. The median drug levels in patients using standard doses were infliximab 2.2 µg/mL (1.4–5.2), adalimumab 4.9 µg/mL (0.8−8.9) and etanercept 3.1 µg/mL (2.3−4.4). There were no differences in drug levels according to disease activity but we found differences in etanercept and infliximab levels according to DMARD use.

Conclusions

Levels of anti-TNFa drugs will change with DMARD treatment.

Keywords:
Anti-TNFα levels
Rheumatoid arthritis
Spondyloarthritis
Resumen
Antecedentes y objetivos

El conocimiento de los niveles de fármacos anti-TNFα puede modificar el tratamiento en pacientes con artritis reumatoide (AR) y espondiloartritis (EspA).

Objetivos

Comparar los niveles de anti-TNFα en pacientes con AR vs EspA, en diferentes situaciones clínicas.

Materiales y métodos

Se realizó un estudio retrospectivo, observacional donde se midieron los niveles de anti-TNFα y la presencia de anticuerpos antifármacos en pacientes seleccionados consecutivamente, utilizando la técnica de ELISA.

Resultados

Se estudiaron 53, 73 y 78 pacientes en tratamiento con infliximab, adalimumab y etanercept, respectivamente. Los niveles medios de fármaco en pacientes con dosis estándar fueron: infliximab 2,2 μg/mL (1,4–5,2), adalimumab 4,9 μg/mL (0,8−8,9) y etanercept 3,1 μg/mL (2,3–4,4). No se encontraron diferencias en los niveles fármacos según la actividad de la enfermedad, sin embargo, hubo diferencias en los niveles de etanercept e infliximab según el uso de fármacos modificadores de la enfermedad sintéticos (FAMEsc).

Conclusiones

Los niveles de fármacos anti-TNFα se verán modificados por el tratamiento con FAMEsc.

Palabras clave:
Niveles de anti-TNFα
Artritis reumatoide
Espondiloartritis

Article

These are the options to access the full texts of the publication Reumatología Clínica (English Edition)
Member
If you are member of Sociedad Española de Reumatología (SER) or the Colegio Mexicano de Reumatología (CMR):
Please go to the member area of SER or CMR and log in.
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Reumatología Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
Idiomas
Reumatología Clínica (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?